<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>Bora Pharmaceuticals Co, Ltd.</title>
    <link>https://www.biospace.com/employer/1820377/bora-pharmaceuticals-co-ltd</link>
    <description>Bora Pharmaceuticals Co, Ltd.</description>
    <language>en-US</language>
    <lastBuildDate>Tue, 01 Dec 2020 16:06:03 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/1820377/bora-pharmaceuticals-co-ltd.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Bora Pharmaceuticals completes acquisition of former GSK facility</title>
      <link>https://www.biospace.com/bora-pharmaceuticals-completes-acquisition-of-former-gsk-facility</link>
      <description>Bora Pharmaceuticals Co., Ltd announced today that the contract development and manufacturing organization (CDMO) has successfully completed the acquisition of GSK's Mississauga, Ontario (Canada ) facility. Initially announced in March 2020 , the site represents Bora Pharmaceuticals' first manufacturing facility in North A</description>
      <pubDate>Tue, 01 Dec 2020 16:06:03 GMT</pubDate>
      <guid>https://www.biospace.com/bora-pharmaceuticals-completes-acquisition-of-former-gsk-facility</guid>
    </item>
    <item>
      <title>Bora Pharmaceuticals Selects Mississauga for its North American Headquarters</title>
      <link>https://www.biospace.com/bora-pharmaceuticals-selects-mississauga-for-its-north-american-headquarters</link>
      <description>Bora Pharmaceuticals, a leading international contract development and manufacturing organization, has selected Mississauga as the location for its first manufacturing facility and corporate headquarters in North America.</description>
      <pubDate>Wed, 02 Dec 2020 18:26:03 GMT</pubDate>
      <guid>https://www.biospace.com/bora-pharmaceuticals-selects-mississauga-for-its-north-american-headquarters</guid>
    </item>
    <item>
      <title>Bora Pharmaceuticals collaborates with Taishin Holdings to launch CDMO investment and M&amp;A plan</title>
      <link>https://www.biospace.com/bora-pharmaceuticals-collaborates-with-taishin-holdings-to-launch-cdmo-investment-and-m-and-a-plan</link>
      <description>Bobby Sheng, chairman of Bora Pharmaceuticals, announced a partnership with Taishin Healthcare Limited Partnership at the 2021 Biotech Investor Forum, whereby the two parties will jointly invest up to NT$3 billion to target forward-looking contract development and manufacturing organizations and contract research organizations, in response to the development trend that is taking place worldwide.</description>
      <pubDate>Thu, 09 Dec 2021 04:06:22 GMT</pubDate>
      <guid>https://www.biospace.com/bora-pharmaceuticals-collaborates-with-taishin-holdings-to-launch-cdmo-investment-and-m-and-a-plan</guid>
    </item>
    <item>
      <title>Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi®</title>
      <link>https://www.biospace.com/evofem-biosciences-to-decrease-cost-of-goods-45-percent-through-new-partnership-with-bora-pharmaceutical-services-for-the-commercial-manufacturing-of-phexxi</link>
      <description>Evofem Biosciences, Inc., announced it has selected Bora Pharmaceuticals Services Inc. Canada as Evofem's new contract manufacturing organization.</description>
      <pubDate>Tue, 10 May 2022 12:56:04 GMT</pubDate>
      <guid>https://www.biospace.com/evofem-biosciences-to-decrease-cost-of-goods-45-percent-through-new-partnership-with-bora-pharmaceutical-services-for-the-commercial-manufacturing-of-phexxi</guid>
    </item>
    <item>
      <title>CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M</title>
      <link>https://www.biospace.com/cdmo-bora-pharmaceuticals-buys-generics-manufacturer-upsher-smith-for-210m</link>
      <dc:creator>Tyler Patchen</dc:creator>
      <description>Taiwanese contract development and manufacturing organization Bora will purchase Minnesota-based Upsher-Smith Laboratories, expanding operations into the U.S. for the first time.</description>
      <pubDate>Thu, 18 Jan 2024 15:07:05 GMT</pubDate>
      <guid>https://www.biospace.com/cdmo-bora-pharmaceuticals-buys-generics-manufacturer-upsher-smith-for-210m</guid>
    </item>
    <item>
      <title>Impax Announces Sale of Taiwan Manufacturing Facility</title>
      <link>https://www.biospace.com/impax-announces-sale-of-taiwan-manufacturing-facility</link>
      <description>This sale supports Impax's operational and cost improvement plans to streamline operations and reduce costs.</description>
      <pubDate>Tue, 19 Dec 2017 13:56:33 GMT</pubDate>
      <guid>https://www.biospace.com/impax-announces-sale-of-taiwan-manufacturing-facility</guid>
    </item>
    <item>
      <title>Vitruvias Therapeutics Inc., Licenses Potassium Chloride ER ANDA (10 and 20 mEq) Capsules to Be Manufactured at Bora Pharmaceutical’s New Zhunan Facility in Taiwan</title>
      <link>https://www.biospace.com/vitruvias-therapeutics-inc-licenses-potassium-chloride-er-anda-10-and-20-meq-capsules-to-be-manufactured-at-bora-pharmaceutical-s-new-zhunan-facility-in-taiwan</link>
      <description>Vitruvias Therapeutics Inc. has agreed to license an approved Potassium Chloride Extended release ANDA.</description>
      <pubDate>Wed, 05 Dec 2018 11:06:47 GMT</pubDate>
      <guid>https://www.biospace.com/vitruvias-therapeutics-inc-licenses-potassium-chloride-er-anda-10-and-20-meq-capsules-to-be-manufactured-at-bora-pharmaceutical-s-new-zhunan-facility-in-taiwan</guid>
    </item>
    <item>
      <title>Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million</title>
      <link>https://www.biospace.com/emergent-biosolutions-announces-sale-of-baltimore-camden-manufacturing-site-to-bora-pharmaceuticals-for-30-million</link>
      <description>Emergent BioSolutions Inc. announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd., a leading international pharmaceutical services company, for a total value of approximately $30 million.</description>
      <pubDate>Thu, 20 Jun 2024 11:06:08 GMT</pubDate>
      <guid>https://www.biospace.com/emergent-biosolutions-announces-sale-of-baltimore-camden-manufacturing-site-to-bora-pharmaceuticals-for-30-million</guid>
    </item>
    <item>
      <title>Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals</title>
      <link>https://www.biospace.com/emergent-biosolutions-finalizes-sale-of-baltimore-camden-manufacturing-site-to-bora-pharmaceuticals</link>
      <description />
      <pubDate>Tue, 20 Aug 2024 17:58:23 GMT</pubDate>
      <guid>https://www.biospace.com/emergent-biosolutions-finalizes-sale-of-baltimore-camden-manufacturing-site-to-bora-pharmaceuticals</guid>
    </item>
    <item>
      <title>Tanvex BioPharma Forging Strategic Alliance With Bora Pharmaceuticals</title>
      <link>https://www.biospace.com/press-releases/tanvex-biopharma-forging-strategic-alliance-with-bora-pharmaceuticals</link>
      <description />
      <pubDate>Fri, 06 Sep 2024 04:55:09 GMT</pubDate>
      <guid>https://www.biospace.com/press-releases/tanvex-biopharma-forging-strategic-alliance-with-bora-pharmaceuticals</guid>
    </item>
  </channel>
</rss>
